profit from every $100 of sales.
$0$100
Arcadia Biosciences
$0.22-1.80% today
-94.4% in 1 year
1-year low $0.141-year high $3.86
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Arcadia Biosciences sold, what it kept, and what it did with the cash.
Sales went from $7.42 million in 2022 to $4.86 million in 2025, with -$2.34 million of profit last year.
SalesProfit
Arcadia Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arcadia Biosciences | No profit yet | ||
 Nutrien | 14.9× · Cheap | ||
 CF Industries Holdings | 12.6× · Cheap | ||
 Industries Qatar Q.P.S.C. | 14.8× · Cheap | ||
 Qinghai Salt Lake Industry Co.,Ltd | 13.6× · Cheap |
AI analysis
An AI analyst reads Arcadia Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7 | 4 | 5 | 5 | |
| 1 | 2 | 2 | 2 | |
| -15 | -6 | -8 | -10 | |
| -15 | -6 | -7 | -10 | |
| -15 | -14 | -7 | -2 | |
| -25.65 | -11.29 | -5.17 | -1.71 | |
| 17.8% | 51.2% | 41.3% | 36.2% | |
| -205.3% | -135.1% | -150.9% | -205.7% | |
| -207.3% | -313.9% | -139.5% | -48.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 29 | 20 | 14 | 7 |
| Cash | 21 | 7 | 4 | 0 |
| Total debt | 2 | 1 | 0 | 0 |
| Total liabilities | 8 | 7 | 7 | 2 |
| 21 | 13 | 6 | 4 | |
| 1 | 1 | 1 | 1 | |
| -52.2% | -34.3% | -94.3% | -190.7% | |
| -73.1% | -108.9% | -113.1% | -56.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -14 | -15 | -10 | -5 | |
| 0 | 0 | 0 | – | |
| -14 | -15 | -10 | -5 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 0.4×
- 0.1×
- –
- –
- -902.3%
- -445.3%
- 0.0%
Profitability
- 36.2%
- -205.7%
- -48.1%
- -200.2%
- -241.4%
- -75.4%
- -219.4%
- -175.1%
- -241.4%
- 0.2%
Growth
- −13.2%
- –
- +50.9%
- –
- +26.6%
Financial health
- -0.0×
- 0.00
- 0.0%
- –
- 3.79
- 3.17
- 0.89
How it ranks in Materials
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 940
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -2.11 | -0.80 | −163.7% |
| Mar 26, 2026 | -0.98 | -0.66 | −48.5% |
| Nov 7, 2025 | 0.62 | -0.54 | +214.8% |
| Aug 14, 2025 | 0.02 | -0.79 | +102.5% |
| May 8, 2025 | 1.90 | -0.98 | +293.9% |
| Mar 20, 2025 | -2.48 | -0.89 | −178.7% |
| Nov 12, 2024 | -0.87 | -0.77 | −13.0% |
| Aug 13, 2024 | 0.78 | 1.55 | −49.7% |
News
DMC Global expects Q4 sales of $154M-$164M amid Arcadia maintenance shutdown and seasonal moderationSeeking Alpha · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
79Pass
Philip Fisher
35No pass
Peter Lynch
29No pass
Joel Greenblatt
0No pass
Charlie Munger
34No pass
Terry Smith
37No pass
Questions about Arcadia Biosciences
Is Arcadia Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arcadia Biosciences AI analysis
What does Arcadia Biosciences do?
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It is in Agricultural Inputs.
Does Arcadia Biosciences pay a dividend?
No. Arcadia Biosciences does not pay a dividend at the moment.
Is Arcadia Biosciences stock halal?
No. Arcadia Biosciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 49% of its market value, at or above the 33% limit. How we check
How has Arcadia Biosciences stock done over the past year?
Down 94.4% over the past twelve months, to $0.22. It traded between $0.14 and $3.86 and is 94.4% below its high.
Who are Arcadia Biosciences's competitors?
The largest listed companies in the same industry are Nutrien, CF Industries Holdings, Industries Qatar Q.P.S.C. and Qinghai Salt Lake Industry Co.,Ltd. The peers table on this page compares their profit, growth and price with Arcadia Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.